Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
P/E ratio for Tiziana Life Sciences Ltd (TLSA)
P/E ratio as of 2023: 0.00
According to Tiziana Life Sciences Ltd's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.00. At the end of 2022 the company had a P/E ratio of -3.76.
P/E ratio history for Tiziana Life Sciences Ltd from 1998 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | -3.76 |
| 2021 | -4.01 |
| 2020 | -12.32 |
| 2019 | -15.39 |
| 2018 | -19.58 |
| 2017 | -35.94 |
| 2016 | -71.18 |
| 2015 | -40.43 |
| 2014 | -22.43 |
| 2013 | -5910.14 |
| 2012 | -2085.83 |
| 2011 | -1591.57 |
| 2010 | -71.06 |
| 2009 | -119.62 |
| 2008 | -31.78 |
| 2007 | -8.24 |
| 2006 | -595.00 |
| 2005 | -504.03 |
| 2004 | -458.94 |
| 2003 | -267.53 |
| 2002 | -105.27 |
| 2001 | -85.27 |
| 2000 | -79.05 |
| 1999 | -297.38 |
| 1998 | -574.76 |